Molecular Basis of Loss Aversion
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whether temporarily boosting dopamine activity or temporarily suppressing norepinephrine activity has an impact on processing of potential gains and losses in financial decision making, social decision making, transaction decision making and moral decision making. Accordingly, participants will complete four decision-making tasks, namely investment task, driving task, trading task, and die task, after taking madopar, propranolol or placebo. Participants' psychological traits and psychiatric symptoms will be assessed once they are enrolled before the first-session day.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: madopar-propranolol-placebo In a within-subjects design, participants will take madopar, propranolol, and placebo each once in three separate sessions. |
Drug: single-dose madopar, single-dose propranolol, and single-dose placebo by order
Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
|
| Other: madopar-placebo-propranolol In a within-subjects design, participants will take madopar, placebo, and propranolol each once in three separate sessions. |
Drug: single-dose madopar, single-dose placebo, and single-dose propranolol by order
Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
|
| Other: propranolol-madopar-placebo In a within-subjects design, participants will take propranolol, madopar, and placebo each once in three separate sessions. |
Drug: single-dose propranolol, single-dose madopar, and single-dose placebo by order
Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
|
| Other: propranolol-placebo-madopar In a within-subjects design, participants will take propranolol, placebo, and madopar each once in three separate sessions. |
Drug: single-dose propranolol, single-dose placebo, and single-dose madopar by order
Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
|
| Other: placebo-propranolol-madopar In a within-subjects design, participants will take placebo, propranolol, and madopar each once in three separate sessions. |
Drug: single-dose placebo, single-dose propranolol, and single-dose madopar by order
Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
|
| Other: placebo-madopar-propranolol In a within-subjects design, participants will take placebo, madopar, and propranolol each once in three separate sessions. |
Drug: single-dose placebo, single-dose madopar, and single-dose propranolol by order
Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
|
Outcome Measures
Primary Outcome Measures
- Choices to invest or not in the investment task [between 1-2 hours after taking the drugs or the placebo]
Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.
- Response times to invest or not in the investment task [between 1-2 hours after taking the drugs or the placebo]
Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.
- Choices to turn or not in the driving task [between 1-2 hours after taking the drugs or the placebo]
Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .
- Response times to turn or not in the driving task [between 1-2 hours after taking the drugs or the placebo]
Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .
- Choices to buy or sell in the trading task [between 1-2 hours after taking the drugs or the placebo]
Participants decide whether or not to buy or sell a product at certain prices.
- Response times to buy or sell in the trading task [between 1-2 hours after taking the drugs or the placebo]
Participants decide whether or not to buy or sell a product at certain prices.
- Reported outcomes in die task [between 1-2 hours after taking the drugs or the placebo]
Participants report the outcome for each throw of the die.
Secondary Outcome Measures
- Affects [before and 1 hour after taking the drugs or the placebo]
Participants' affects will be assessed using the Positive and Negative Affective Scale (PANAS).Scores can range from 10 to 50 for both the Positive and Negative Affect, with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 25-40 years old (including boundary value).
-
Elementary school education or above, able to understand the research content.
-
Body temperature, blood pressure, heart rate, respiratory rate, and electrocardiogram are all normal. Among them, the blood pressure range is 100-139/70-89 mmHg, and the heart rate range is 60-85 beats/min.
Exclusion Criteria:
-
Vulnerable groups, including people with mental illness, cognitive impairment, critically ill subjects, minors, pregnant women, illiterates, etc.
-
Family history of genetic diseases.
-
Major physical diseases, including cardiovascular, respiratory, digestive, renal, endocrine, blood and other systemic diseases.
-
History of alcohol/drug dependence.
-
Lactating women.
-
The cardiopulmonary function test results are poor.
-
Have ever taken madopar or propranolol for medical use.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sir Run Run Shaw Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- 20230496